| Title | Cardiovascular and Hematological Disorders - Drug Targets |
| Abbreviation | Cardiovasc. Hematol. Disord. - Drug Targets |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Cardiology and Cardiovascular Medicine (Q3); Hematology (Q3); Medicine (miscellaneous) (Q3); Pharmacology (Q3); Molecular Medicine (Q4) |
| h-index | 44 |
| Overall Rank/Ranking | 16147 |
| SCImago Journal Rank (SJR) | 0.270 |
| Impact Score | 1.08 |
| Publisher | Bentham Science Publishers B.V. |
| Country | United Arab Emirates |
| ISSN | 1871529X |
| Best Quartile | Q3 |
| Coverage History | 2006-2022 |
Cardiovascular and Hematological Disorders - Drug Targets is a journal covering the technologies/fields/categories related to Cardiology and Cardiovascular Medicine (Q3); Hematology (Q3); Medicine (miscellaneous) (Q3); Pharmacology (Q3); Molecular Medicine (Q4). It is published by Bentham Science Publishers B.V.. The overall rank of Cardiovascular and Hematological Disorders - Drug Targets is 16147. According to SCImago Journal Rank (SJR), this journal is ranked 0.270. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 44. The best quartile for this journal is Q3.
The ISSN of Cardiovascular and Hematological Disorders - Drug Targets journal is 1871529X. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Cardiovascular and Hematological Disorders - Drug Targets is cited by a total of 122 articles during the last 3 years (Preceding 2022).
The Impact IF 2022 of Cardiovascular and Hematological Disorders - Drug Targets is 1.08, which is computed in 2023 as per its definition. Cardiovascular and Hematological Disorders - Drug Targets IF is decreased by a factor of 0.01 and approximate percentage change is -0.92% when compared to preceding year 2021, which shows a falling trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2022 of Cardiovascular and Hematological Disorders - Drug Targets is 1.08. If the same downward trend persists, Impact IF may fall in 2023 as well.
| Year | Impact IF |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 1.08 |
| 2021 | 1.09 |
| 2020 | 1.57 |
| 2019 | 1.41 |
| 2018 | 1.00 |
| 2017 | 1.13 |
| 2016 | 1.33 |
| 2015 | 1.81 |
| 2014 | 1.78 |
Cardiovascular and Hematological Disorders - Drug Targets has an h-index of 44. It means 44 articles of this journal have more than 44 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Cardiovascular and Hematological Disorders - Drug Targets is 1871529X. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Cardiovascular and Hematological Disorders - Drug Targets is 16147. According to SCImago Journal Rank (SJR), this journal is ranked 0.270. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 0.270 |
| 2021 | 0.300 |
| 2020 | 0.365 |
| 2019 | 0.330 |
| 2018 | 0.293 |
| 2017 | 0.513 |
| 2016 | 0.616 |
| 2015 | 0.760 |
| 2014 | 0.660 |
| Year | Ranking |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 16147 |
| 2021 | 14776 |
| 2020 | 12956 |
| 2019 | 13437 |
| 2018 | 13933 |
| 2017 | 9042 |
| 2016 | 7655 |
| 2015 | 6239 |
| 2014 | 7054 |
Cardiovascular and Hematological Disorders - Drug Targets is published by Bentham Science Publishers B.V.. It's publishing house is located in United Arab Emirates. Coverage history of this journal is as following: 2006-2022. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Cardiovascular and Hematological Disorders - Drug Targets is Cardiovasc. Hematol. Disord. - Drug Targets. This abbreviation ('Cardiovasc. Hematol. Disord. - Drug Targets') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Cardiology and Cardiovascular Medicine (Q3); Hematology (Q3); Medicine (miscellaneous) (Q3); Pharmacology (Q3); Molecular Medicine (Q4), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Cardiovascular and Hematological Disorders - Drug Targets latest impact IF is 1.08. It's evaluated in the year 2022. The highest and the lowest impact IF or impact score of this journal are 1.81 (2015) and 1.00 (2018), respectively, in the last 9 years. Moreover, its average IS is 1.36 in the previous 9 years.
The Cardiovascular and Hematological Disorders - Drug Targets has an SJR (SCImago Journal Rank) of 0.270, according to the latest data. It is computed in the year 2023. In the past 9 years, this journal has recorded a range of SJR, with the highest being 0.760 in 2015 and the lowest being 0.270 in 2022. Furthermore, the average SJR of the Cardiovascular and Hematological Disorders - Drug Targets over the previous 9-year period stands at 1.36.
The latest h-index of the Cardiovascular and Hematological Disorders - Drug Targets is 44.
The Cardiovascular and Hematological Disorders - Drug Targets is published by the Bentham Science Publishers B.V., with its country of publication being the United Arab Emirates.
The Cardiovascular and Hematological Disorders - Drug Targets is currently ranked 16147 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 9 years, this journal has experienced varying rankings, reaching its highest position of 6239 in 2015 and its lowest position of 16147 in 2022.
The standard ISO4 abbreviation for the Cardiovascular and Hematological Disorders - Drug Targets is Cardiovasc. Hematol. Disord. - Drug Targets.
Cardiovascular and Hematological Disorders - Drug Targets is classified as a journal that the Bentham Science Publishers B.V. publishes.
The Cardiovascular and Hematological Disorders - Drug Targets encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Cardiovascular and Hematological Disorders - Drug Targets is assigned the following International Standard Serial Numbers (ISSN): 1871529X.
The best quartile for the Cardiovascular and Hematological Disorders - Drug Targets is Q3 (2022).
The Cardiovascular and Hematological Disorders - Drug Targets coverage history can be summarized as follows: 2006-2022.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Business Economics and Management | journal | 10343 | Vilnius Gediminas Technical University | 45 | 2.81 |
| Indian Journal of Plastic Surgery | journal | 16018 | Thieme Medical Publishers Inc. | 37 | 0.65 |
| Journal of Applied Business Research | journal | 23890 | 29 | 0.28 | |
| Entrepreneurship Theory and Practice | journal | 338 | Wiley-Blackwell | 185 | 12.75 |
| Discourse | journal | 6621 | Routledge | 59 | 2.11 |
| Sex Education | journal | 5168 | Routledge | 41 | 2.82 |
| Howard Journal of Communications | journal | 9564 | Taylor and Francis Ltd. | 36 | 1.66 |
| Palaeontographica Abteilung B: Palaeophytologie | book series | 15138 | E. Schweizerbart'sche Verlagsbuchhandlung | 16 | 2.20 |
| Sapporo Medical Journal | journal | 20468 | Cancer Research Institute, Sapporo Medical University | 3 | 0.00 |
| Archives of the Balkan Medical Union | journal | 23243 | Balkan medical union | 10 | 0.24 |
| Year | Impact Score (IS) |
|---|---|
| 2023/2024 | Coming Soon |
| 2022 | 1.08 |
| 2021 | 1.09 |
| 2020 | 1.57 |
| 2019 | 1.41 |
| 2018 | 1.00 |
| 2017 | 1.13 |
| 2016 | 1.33 |
| 2015 | 1.81 |
| 2014 | 1.78 |
